The efficacy and safety of 0.5% Levofloxacin versus fortified Cefazolin and Amikacin ophthalmic solution for the treatment of suspected and culture-proven cases of infectious bacterial keratitis: A comparative study

Asian Biomedicine

Volumn 5, Issue 1, 2011, Pages 77-83

  Kasetsuwan, Ngamjit ^a   Tanthuvanit, Pinnita ^b   Reinprayoon, Usanee ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Bacterial keratitis; Fluoroquinolone; Fortified topical antibiotics; Levofloxacin

Indexed keywords

AMIKACIN; CEFAZOLIN; LEVOFLOXACIN;

ARTICLE; BACTERIAL KERATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; ULCER HEALING; UNSPECIFIED SIDE EFFECT;

EID: 84871532877     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.5372/1905-7415.0501.009     Document Type: Article

References (24)

1. Boonpasart S, Kasetsuwan N, Puangsricharern V, Pariyakanok L, Jittpoonkusol T. Infectious keratitis at King Chulalongkorn Memorial Hospital: a 12-year retrospective study of 391 cases. J Med Assoc Thai. 2002; 85:217S-30S.
2. American Academy of Ophthalmology Vision Rehabilitation Panel. Preferred Practice Pattern® Guidelines. Bacterial Keratitis. San Francisco: American Academy of Ophthalmology; 2008. Available at: http://www.aao.org/ppp.
3. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991; 112:34S-47S.
4. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995; 113:1257-65.
5. Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology. 1997; 104:1902-9.
6. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004; 49:73S-8S.
7. Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol. 2007; 55:15-9. (Pubitemid 46065927)
8. Jones DB. Decision making in the management of microbial keratitis. Ophthalmology. 1981; 88:814-20. (Pubitemid 11039470)
9. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye. 1999; 13:744-7. (Pubitemid 30050501)
10. Gangopadhyay N, Daniell M, Weih L, Taylor HR. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol. 2000; 84:378-84. (Pubitemid 30255486)
11. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolones resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-8. (Pubitemid 30191477)
12. Daniell M. Overview: initial antimicrobial therapy for microbial keratitis. Br J Ophthalmol. 2003; 87:1172-4. (Pubitemid 37064899)
13. Parmar P, Salman A, Kalavathy CM, Kaliamurthy J, Prasanth DA, Thomas PA, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006; 141:282-6.
14. Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology. 2007; 114:1622-9. (Pubitemid 47332654)
15. Holland EJ, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin. 2007; 23:2955-60.
16. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003; 136:500-5. (Pubitemid 37101247)
17. Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humor levels of topically applied levofloxacin in human eyes. Curr Eye Res. 2002; 24:403-6. (Pubitemid 36042894)
18. Colin J, Simonpoli S, Geldsetzer K, Ropo A. Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. Acta Ophthalmol Scand. 2003; 81:611-3. (Pubitemid 37527638)
19. Bucci FA Jr. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol. 2004; 137:308-12.
20. Healy DP, Holland EJ, Nordlund ML, Dunn S, Chow C, Lindstrom RL, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea. 2004; 23:255-63. (Pubitemid 38401902)
21. Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001; 131:131-3. (Pubitemid 32037020)
22. Tanhehco TY, Chiavetta SV 3rd, Lee PP, Fowler AM, Afshari NA. "Cracked-mud" ciprofloxacin precipitates on a corneal graft. Ophthalmic Surg Lasers Imaging. 2005; 36:252-3. (Pubitemid 40733775)
23. Awwad ST, Haddad W, Wang MX, Parmar D, Conger D, Cavanagh HD. Corneal intrastromal gatifloxacin crystal deposits after penetrating keratoplasty. Eye Contact Lens. 2004; 30:169-72. (Pubitemid 43196967)
24. Erjongmanee S, Kasetsuwan N, Phusitphoykai N, Puangsricharern V, Pariyakanok L. Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. J Med Assoc Thai. 2004; 87:83S-90S.